What the Label on a Dispensed Prescription Has to Say

Answer first: five items, in exchange for an exemption

The provision is 21 U.S.C. 353(b)(2). A drug dispensed by filling or refilling a prescription "shall be exempt from the requirements of section 352 of this title" — the misbranding section — with named exceptions, "if the drug bears a label containing the name and address of the dispenser, the serial number and date of the prescription or of its filling, the name of the prescriber, and, if stated in the prescription, the name of the patient, and the directions for use and cautionary statements, if any, contained in such prescription."

That is the whole federal list for the pharmacy's own label: who dispensed it and where; the prescription's serial number and the date of the prescription or of its filling; the prescriber's name; the patient's name if the prescription states it; and the directions and cautionary statements the prescription contains.

The structure is a trade. A manufacturer's carton has to satisfy an elaborate set of labeling requirements. Once a pharmacy fills a prescription, the great majority of those requirements fall away, and this short list takes their place. State pharmacy law adds more, and this article does not describe state requirements.

What the exemption does not cover

The exemption is not complete, and the exceptions are named by paragraph. It applies "except paragraphs (a), (i)(2) and (3), (k), and (l), and the packaging requirements of paragraphs (g), (h), and (p)."

Reading those against the misbranding section shows what survives. Paragraph (a) is the central rule: a drug is misbranded if its labeling is false or misleading in any particular. Paragraph (i)(2) covers a drug that is an imitation of another drug, and (i)(3) a drug offered for sale under the name of another drug. The preserved packaging requirements are paragraph (g), on drugs recognized in an official compendium, which must be packaged and labeled as prescribed there; paragraph (h), on drugs the Secretary has found liable to deterioration, which must be packaged as required and bear the required precautionary statement; and paragraph (p), which makes a drug misbranded if its packaging or labeling violates an applicable regulation issued under the poison prevention packaging provisions of Title 15.

One detail is visible only by reading the current text of the misbranding section: paragraphs (k) and (l), which the exemption still names, were repealed in 1997. The cross-reference outlived the paragraphs.

The practical point is that the exemption never reaches the false-or-misleading rule. A pharmacy label that misstates the drug, the strength or the directions is not covered by it.

Two circumstances that switch the exemption off

The same paragraph ends with a sentence that removes the exemption in two situations: "This exemption shall not apply to any drug dispensed in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail, or to a drug dispensed in violation of paragraph (1) of this subsection."

The second of those is straightforward. Paragraph (1) is the requirement that a prescription drug be dispensed only on a written prescription of a practitioner licensed to administer it, on an oral prescription promptly reduced to writing and filed by the pharmacist, or by refilling such a prescription where the prescriber has authorized the refill. It ends with a sentence that supplies the enforcement hook: "The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale."

The first is the older and stranger clause. Diagnosis by mail is not defined in the section, and this article takes no position on how it applies to any modern practice or to any company. What can be said from the text alone is that Congress wrote a carve-out aimed at a business of dispensing drugs on a diagnosis made at a distance, and that the carve-out removes the labeling exemption rather than creating a separate offense. A reader who encounters the phrase in a legal document is looking at a clause that has been in the statute a long time and whose scope is a question for courts and regulators.

The symbol rule runs in both directions

The same subsection contains a rule about the prescription-only symbol, and it is symmetrical.

A drug subject to the prescription requirement "shall be deemed to be misbranded if at any time prior to dispensing the label of the drug fails to bear, at a minimum, the symbol 'Rx only.'" And a drug to which the prescription requirement does not apply "shall be deemed to be misbranded if at any time prior to dispensing the label of the drug bears the symbol described in subparagraph (A)."

So the statement is required where the category applies and prohibited where it does not. Both directions are misbranding. The phrase prior to dispensing is what limits the rule to the supply chain rather than to the vial handed over the counter.

There is a related provision worth knowing for context: the Secretary "may by regulation remove drugs subject to section 355 of this title from the requirements of paragraph (1)... when such requirements are not necessary for the protection of the public health." Prescription status is a category a drug can be moved out of by regulation, not a permanent property.

What the manufacturer tells the pharmacy about the container

One piece of the chain is easy to miss because it is addressed to the pharmacist rather than to the patient. Among the conditions of the manufacturer's own labeling exemption, 21 CFR 201.100 requires the label to bear "A statement directed to the pharmacist specifying the type of container to be used in dispensing the drug product to maintain its identity, strength, quality, and purity."

The regulation gives its own example of the form that takes where compendial standards exist — "Dispense in tight, light-resistant container as defined in the National Formulary" — and provides that where no compendial standard applies, the specific container or types of containers known to be adequate must be described. It also relieves the requirement for products "packaged in unit-dose, unit-of-use, on other packaging format in which the manufacturer's original package is designed and intended to be dispensed to patients without repackaging."

That last clause explains a difference readers notice between products. Something dispensed in the manufacturer's own package is not being repackaged, so there is no container instruction for a pharmacist to follow. Something counted or poured into a pharmacy container is, and the instruction on the bulk label is what governs which container it goes into.

What to look for on your own label, and what it cannot tell you

The federal list is short enough to check: the dispenser's name and address, a serial number and a date, the prescriber's name, the patient's name where the prescription stated it, and the directions and cautionary statements the prescription contained.

What that list does not include is as informative as what it does. It does not require the manufacturer's name, the lot number, an expiration date, or the full professional labeling — those live on the manufacturer's package and in the prescribing information, which is where the adequate-information requirement puts them. A dispensed label is a record of a transaction and a set of instructions from a prescriber, not a summary of a drug.

Two limits are worth stating plainly. This is federal law only; state pharmacy law imposes further requirements that vary, and nothing here describes them. And the exemption that makes the short list possible has never covered the rule against labeling that is false or misleading in any particular, which continues to apply to the dispensed container.